EVEREKLİOĞLU, C. Et Al. 2023. Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behcet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation. INTERNATIONAL OPHTHALMOLOGY , vol.43, no.12 , 4461-4472.

EVEREKLİOĞLU, C., SÖNMEZ, H. K., Sevim, D., ARDA, H., ŞENER, H., POLAT, O. A., ... HOROZOĞLU, F.(2023). Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behcet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation. INTERNATIONAL OPHTHALMOLOGY , vol.43, no.12, 4461-4472.

EVEREKLİOĞLU, CEM Et Al. "Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behcet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation," INTERNATIONAL OPHTHALMOLOGY , vol.43, no.12, 4461-4472, 2023

EVEREKLİOĞLU, CEM Et Al. "Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behcet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation." INTERNATIONAL OPHTHALMOLOGY , vol.43, no.12, pp.4461-4472, 2023

EVEREKLİOĞLU, C. Et Al. (2023) . "Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behcet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation." INTERNATIONAL OPHTHALMOLOGY , vol.43, no.12, pp.4461-4472.

@article{article, author={CEM EVEREKLİOĞLU Et Al. }, title={Adalimumab rapidly controls both anterior and posterior inflammation in patients with ocular Behcet syndrome and non-infectious uveitis refractory to conventional therapy: a prospective, 6-month follow-up investigation}, journal={INTERNATIONAL OPHTHALMOLOGY}, year=2023, pages={4461-4472} }